Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835375 Phase 2 Study in Adults With Primary Immune Thrombocytopenia
2021-002897-19Phase 2Active
- Sponsor
- Pfizer
- Start
- Dec 2021
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PF-06835375 in immune thrombocytopenia (ITP), sponsored by Pfizer. Primary endpoint: Log2 (platelet count) at Week 12. Started Dec 2021; status: active.
02
Drugs
PF-06835375
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2021-002897-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002897-19.